💨 Abstract

India's J B Chemicals & Pharmaceuticals reported a 22% increase in Q3 profit, driven by strong domestic demand for chronic and acute condition drugs. Revenue grew 14% to 9.63 billion rupees. The domestic formulations business, which accounts for 60% of total revenue, grew by 22%. A 33% rise in contract drugs manufacturing boosted the international formulations business by 4%.

Courtesy: theprint.in

Summarized by Einstein Beta 🤖